Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2018-03-28 Report Publication Anno…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
2018.03.28 PR GENFIT EASL ILC 2018
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 28th, 2018, announcing that GENFIT will present new data at the EASL 2018 Annual Congress in April. It details the specific abstracts, poster presentations, and KOL events related to their NASH research (elafibranor, NIS4 algorithm, etc.). This type of announcement, detailing upcoming participation in a scientific conference, is a standard form of corporate communication to investors and the public regarding research progress. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER). Since it is a general corporate announcement detailing scientific progress and upcoming presentations, and does not fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements that don't fit elsewhere, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of participation. Given the context of corporate disclosure, RNS is the most appropriate fallback for a general press release about conference participation.
2018-03-28 English
2018.03.28 CP GENFIT EASL ILC 2018
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2018, announcing that GENFIT will present new data at the International Liver Congress 2018 (EASL ILC 2018) regarding NASH diagnostics, treatment combinations, and deep-learning image analysis. It details the specific abstracts being presented and mentions related events like a KOL lunch and a satellite symposium. This type of announcement, detailing upcoming scientific presentations or corporate activities related to research and development milestones, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing scientific progress and upcoming investor engagement rather than a full financial report (10-K, IR) or a simple earnings highlight (ER), 'Investor Presentation' (IP) is the most fitting category, as these releases often precede or accompany investor-focused presentations about pipeline progress. It is not a formal regulatory filing like 10-K or a simple earnings release.
2018-03-28 French
2018.01.23 CP GENFIT PSP FDA
Earnings Release Classification · 92% confidence The document is a press release dated January 23, 2018, announcing the official launch of a pediatric clinical program for elafibranor in NASH, following agreements with the EMA (PIP) and FDA (PSP). It details clinical trial progress, scientific rationale, and includes quotes from management and external experts. This format—a formal announcement of significant corporate/clinical development news, often released outside of mandatory periodic filings—is characteristic of an Earnings Release (ER) or a general press release. Since it focuses on a major operational/clinical milestone rather than just financial results (ER) or management changes (MANG), and it is not a full periodic report (10-K, IR), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's a standalone announcement. Given the content is a major corporate update announcing the start of a trial based on regulatory agreements, it functions as a key operational announcement. In the context of the provided definitions, 'ER' (Earnings Release) is often used for major operational updates accompanying financial periods, but this is a specific clinical/regulatory milestone announcement. Since it is a formal announcement of a significant event (launching a pediatric trial after regulatory approval), and it is not a transcript (CT), presentation (IP), or a formal statutory report (10-K, AR, IR), the most appropriate general category for a significant, non-financial-summary announcement is often 'RNS' (Regulatory Filings) or 'ER' if it's considered a major operational update. However, since it is a detailed announcement of a clinical/regulatory event, and not just a brief notice, it is more substantial than a typical RNS fallback. Given the context of biotech/pharma announcements, these detailed press releases often fall under the 'ER' umbrella when they are the primary communication vehicle for a major update, even if not strictly tied to quarterly earnings. If we must choose the best fit among the specific options, and recognizing it's a detailed announcement of a major corporate/clinical event, 'ER' is plausible, but 'RNS' (Regulatory Filings/General Announcement) is the safest fit for a non-standard, non-periodic, significant corporate press release that doesn't fit other specific categories like MANG or DIV. I will classify it as ER as it functions as a major operational update announcement, similar to how earnings releases function for operational milestones in this sector, but I acknowledge RNS is also a possibility. Re-evaluating: This is a press release announcing a clinical program launch based on regulatory feedback. It is not a financial supplement (XLSX), a proxy (PSI), or a management discussion (MDA). It is a major corporate announcement. I will lean towards ER as the primary communication vehicle for significant company news, even if not strictly financial results. FY 2018
2018-01-23 French
2018.01.23 PR GENFIT PSP FDA
Regulatory Filings Classification · 95% confidence The document is explicitly titled '# PRESS RELEASE' and contains standard press release formatting, including a headline, bullet points summarizing key news, a date/location stamp, and boilerplate 'ABOUT' and 'FORWARD LOOKING STATEMENT' sections. The content announces a significant operational/regulatory milestone: the agreement by the FDA and EMA on the Pediatric Study Plan (PSP/PIP) for elafibranor in NASH, leading to the launch of a pediatric clinical trial. This type of announcement, focusing on regulatory progress and operational updates rather than comprehensive financial results (like 10-K or IR) or specific insider trading (DIRS), is best classified as a general Regulatory Filing or an announcement that falls under the broad scope of investor relations communications. Since it is not a full financial report, earnings release, or a specific management/board change, and it is a formal announcement of a regulatory step, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered by more specific codes. It is not short enough to be a simple RPA, as it contains substantial detail and context.
2018-01-23 English
2018.01.12 PR GENFIT Half Year report of Liquidity Contract
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces the "HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC" as of December 31, 2017, comparing it to the previous half-year report date of June 30, 2017. This document provides specific financial/contractual updates for an interim period (half-year) but is presented as a press release, not the comprehensive financial report itself (which would be an IR or 10-K). Since it details financial status for a period shorter than a year, it relates to interim reporting. However, the content is very specific: reporting on a liquidity contract, which is a specialized financial arrangement. Given the options, this is not a standard Interim Report (IR) which usually contains full statements. It is a specific announcement regarding a financial arrangement. It is too specific for a general Earnings Release (ER) or Regulatory Filing (RNS). The closest fit among the specific financial categories is difficult. Since it reports on a financial status for a period shorter than a year, it touches upon interim reporting, but the core subject is a liquidity contract update. Because it is a press release announcing a specific financial status update for a period shorter than a year, and it is not a full financial statement, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the liquidity contract is viewed as a financing tool. Given the nature of reporting on a specific contract's status mid-year, and the document being a short press release, RNS is the safest fallback for specific, non-standard financial disclosures. However, since it reports on a financial position for a period shorter than a year, and it is not a comprehensive IR, I will re-evaluate. The document is a press release detailing a specific financial metric (liquidity contract status) for a half-year period. This is a common type of disclosure that often falls under general regulatory announcements. I will classify it as RNS as it is a specific, non-standard financial disclosure announcement that doesn't fit the comprehensive IR or ER definitions.
2018-01-12 English
2018.01.12 CP GENFIT Bilan semestriel contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and specifically details the "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC CIC" (Semi-annual statement of the liquidity contract with CIC). This document reports on the status of a liquidity contract (share buyback/stabilization arrangement) as of a specific date (December 31, 2017), comparing it to the previous period. This activity—the management of the company's own shares through a liquidity contract—falls directly under the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs. Although it is a press release, the core subject matter is the transaction itself, not just the announcement of a report (which would suggest RPA or RNS). Since POS is a specific category for share transactions, it is preferred over the general RNS fallback. The document length is relatively short (under 5,000 characters), but the content is substantive regarding the share transaction details, not just a placeholder announcement.
2018-01-12 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.